Could kids with bone cancer go home sooner after chemo?
NCT ID NCT07560826
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether children, teens, and young adults with newly diagnosed osteosarcoma can safely leave the hospital when their methotrexate levels are slightly higher than usual after standard chemotherapy. The goal is to shorten hospital stays without increasing side effects or readmissions. About 46 participants aged 22 or younger will be monitored, and researchers will also try to grow tumor samples in the lab for future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- High-dose methotrexate
- What this could lead to
- If successful, this could allow earlier hospital discharge after chemotherapy, reducing hospital stays and costs for young osteosarcoma patients.
- What could go wrong
- This is a small, early-phase trial with only 46 participants, so results may not apply to all patients. There is a risk of side effects or rehospitalization with higher methotrexate levels.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA IN ADOLESCENTS AND YOUNG ADULTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina, 27157, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
East Carolina University
Greenville, North Carolina, 27834, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
-
Novant Health Hemby Children's Hospital
Charlotte, North Carolina, 28204, United States
-
Prisma Health Midlands
Columbia, South Carolina, 29203, United States
-
Prisma Health Upstate
Greenville, South Carolina, 29605, United States
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.